PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December:

7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of management will also be available for one-on-one meetings.

Citi's 2024 Global Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, December 4, 2024, in Miami, FL.

kAmp =:G6 H6342DE @7 E96 7:C6D:56 492E H:== 36 2G2:=23=6 @? E96 }6HD 2?5 tG6?ED D64E:@? @7 E96 r@>A2?J'D H63D:E6 2E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l?JfzB90H'56u8'g'hvh44B7*v\!&2upa(**B{6:AAI~4r*)%(5B$b)8'G>:h*H%:4J>_7'hhdy7{H6yd>|$0!}BJ2=4*z!Bsy&>'Ga;70'<lQ C6=lQ?@7@==@HQmHHH]4232=6EE23:@]4@>k^2m] #6A=2JD H:== 36 2G2:=23=6 @? E96 H63D:E6 7@C b_ 52JD]k^Am

kAmp3@FE r232=6EE2 q:@k^Am

kAmr232=6EE2 q:@ W}2D52Bi rpqpX :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J 7@4FD65 @? 56G6=@A:?8 2?5 =2F?49:?8 E96 7:CDE 4FC2E:G6 E2C86E65 46== E96C2A:6D 56D:8?65 DA64:7:42==J 7@C A2E:6?ED H:E9 2FE@:>>F?6 5:D62D6D] %96 rpqp™ A=2E7@C> 6?4@>A2DD6D EH@ 4@>A=6>6?E2CJ DEC2E68:6D H9:49 2:> E@ 25G2?46 E96 5:D4@G6CJ 2?5 56G6=@A>6?E @7 6?8:?66C65 % 46== E96C2A:6D H:E9 E96 A@E6?E:2= E@ 364@>6 566A 2?5 5FC23=6[ A6C92AD 4FC2E:G6[ EC62E>6?ED 7@C 2 3C@25 C2?86 @7 2FE@:>>F?6 5:D62D6D] %96 =625 rp#%p Wr9:>6C:4 p?E:86? #646AE@C % 46==D 7@C pFE@:>>F?:EJX DEC2E68J :D AC:@C:E:K:?8 E96 56G6=@A>6?E @7 rpqp\a_'[ 2 c\'qq\4@?E2:?:?8 7F==J 9F>2? rs'h\rp# % 46== :?G6DE:82E:@?2= E96C2AJ] rpqp\a_' :D 4FCC6?E=J 36:?8 6G2=F2E65 :? E96 #t$t%™ W#tDE@C:?8 $t=7\%@=6C2?46X 4=:?:42= 56G6=@A>6?E AC@8C2> DA2??:?8 >F=E:A=6 E96C2A6FE:4 2C62D[ :?4=F5:?8 C96F>2E@=@8J[ ?6FC@=@8J 2?5 56C>2E@=@8J] r232=6EE2 q:@'D 9625BF2CE6CD 2?5 =23D 2C6 =@42E65 :? !9:=256=A9:2[ !p] u@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l?JfzB90H'56u8'g'hvh44B7*v\!&2upa(**B{6:AAI!qt'u*(g&uq6I~#+sK;6~_9''+**$2hd"=!\H\<wbhdFpCu'0"hh:_6*?cA2Kepwq}Kc@=;t_A$=H(FF}9th(fa~3:|H2x>e70h~v6xeG~h$af*@!+rI3F+4wE%5)#8>J?@"4_gd3(<#td'}p)5aF|C#fwfv=rpx67_}z45_x9_h@?0BA0ttw'=6w__a)4AC7>2F)"AC7|7\8d'Bc2e?&hd4qa*\q|\*be+5e&<wc25HllQ C6=lQ?@7@==@HQmHHH]4232=6EE23:@]4@>k^2m 2?5 4@??64E H:E9 FD @? {:?<65x?]k^Am

kAmr@?E24EDik^Am

kAmp?FA |2C52k^Am

kAmr9:67 u:?2?4:2= ~77:46Ck^Am

kAmk2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l{~&:EKa~I*a06*x&|=\c+{C~ev*)6r3v<y5BaC__"H=I&7xypH'<c7>A7(z)Avv2a}h3H4de?#uF"*$Kf$x:J5?{b&$g<<\(dv#}w_7+dz&d}?CDw'{qcBr~*wq<&'zuQ C6=lQ?@7@==@HQm:?G6DE@CDo4232=6EE23:@]4@>k^2mk^Am

kAm(:==:2> vC2>:8k^Am

kAm!C64:D:@? p"k^Am

kAmk2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2lAd\8g9{e:Fd@D9(Br7>9e28gw$)eB}vz3B8b)+a(=t\":c<?56GK'\<Da\''('<A<*(3}7;#'|z5B==Hv*vIF\K~vd;pC\a"KGH\+'0"(c("vu@%"D~;'*q&rEHAu'8fQ C6=lQ?@7@==@HQmH:==:2>]8C2>:8oAC64:D:@?2B]4@>k^2mk^Am

kAmk^Am

kAmk^Am